MedPath

Osteopathy on IBS Symptoms in Patients With Ulcerative Colitis in Remission

Not Applicable
Terminated
Conditions
Ulcerative Colitis
Irritable Bowel Syndrome
Interventions
Other: Osteopathy
Registration Number
NCT04159311
Lead Sponsor
Clinique Paris-Bercy
Brief Summary

Type : interventional, randomized single blind study Aim : to evaluate 3 sessions of osteopathy on IBS-like symptoms associated with ulcerative colitis in remission Number of patients : 50 (randomization 1:1) Duration of the inclusion period : 2 years Primary end-point : Irritable Bowel Syndrome Severity Scoring System (IBS SSS) at 3 months

Detailed Description

Osteopathy has been shown to be effective in IBS patients in few studies and to improve IBS-like symptoms in a short series of Crohn patients. IBS-like symptoms are frequent in patients with ulcerative colitis in remission (about 20 %).

The aim of this interventional, randomized single blind study is to evaluate the impact of 3 sessions of osteopathy on Irritable Bowel Syndrome symptoms in 50 patients (randomisation 1:1) with ulcerative colitis in remission (defined by fecal calprotectin \< 200 µg/g).

The two group of patients will have 4 sessions of osteopathy (M0, M1, M2, M3). The "treated group" will have 3 sessions of osteopathy testing followed by osteopathy treatment (M0, M1, M2) and a final testing session at M3. The "untreated group" will have 4 sessions of only testing osteopathy (M0, M1, M2, M3).

Primary end-points : Irritable Bowel Syndrome Severity Scoring System (IBS SSS) at 3 months (M3) Secondary end-points : Inflammatory Bowel Disease Questionnaire ol, Functional Assessment of Chronic Illness Therapy-Fatigue at M3, evaluation of osteopathic dysfunctions between M0 and M3, questionnaire for use of medication for IBS between M0 and M3

Recruitment & Eligibility

Status
TERMINATED
Sex
All
Target Recruitment
8
Inclusion Criteria
  • Signed informed consent
  • Age between 18 and 90
  • Patient with ulcerative colitis (whatever the Montreal grade, E1, E2 or E3) In clinical remission for at least 3 months and with fecal calprotectin < 200 µg/g
  • No modification of Ulcerative Colitis treatment for at least 3 months
  • Patient with IBS-liked symptoms defined as in Rome IV classification for Irritable Bowel Syndrome
  • Patient with Irritable Bowel Syndrome Severity Scoring System > 75 at screening
  • Patient affiliated to the French Social Security regimen
Exclusion Criteria
  • Patient refusal
  • Patient < 18 yoa
  • Patient with colonic or ileal stenosis
  • Patient diagnosed as undetermined colitis
  • Patient not in remission for Ulcerative Colitis as defined by an endoscopic Mayo score > 1 within the 3 months preceding the inclusion and/or fecal calprotectin > 200 µg/g at inclusion
  • Osteopathy session(s) within 1 month before inclusion
  • Patient with Inflammatory rheumatic disorders (ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis)
  • Patient with Irritable Bowel Syndrome Severity Scoring System <75 at screening
  • Patient above 18 yoa with law guardianship

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Untreated groupOsteopathyThe "untreated group" will have 4 sessions of only testing osteopathy (M0, M1, M2, M3).
Treated groupOsteopathyThe "treated group" will have 3 sessions of osteopathy testing followed by osteopathy treatment (M0, M1, M2) and a final testing session at M3.
Primary Outcome Measures
NameTimeMethod
Evaluate the score change of Irritable Bowel Syndrome Severity Scoring System (IBS SSS)Month 1, Month 2, Month 3, Month 4

index of severity of Irritable Bowel Syndrome symptoms

Secondary Outcome Measures
NameTimeMethod
IBDQol : Inflammatory Bowel Disease QuestionnaireMonth 1, Month 2, Month 3, Month 4

Index of quality of life dedicated to Inflammatory Disease Bowel patients : the score is high, better the quality of life

Questionnaire for use of medication for Irritable Bowel SyndromeMonth 1, Month 2, Month 3, Month 4

if treatment modification, dose reduction or change in treatment

FACIT-F : Functional Assessment of Chronic Illness Therapy-FatigueMonth 1, Month 2, Month 3, Month 4

Validated fatigue score with question about quality of life 45/5000

if the score is high, the patient is tired

Evaluation of osteopathic dysfunctionsMonth 1, Month 2, Month 3, Month 4

it will be interesting to see if patients with remission-prone RCH have similar osteopathic dysfunctions at the beginning of the study, and then if the management during the study influences or not these osteopathic dysfunctions.

Osteopathic dysfunction is an alteration of the mobility, viscoelasticity or texture of somatic system components. It is accompanied or not by a painful sensibility.

Trial Locations

Locations (1)

Clinique Paris Bercy

🇫🇷

Charenton Le Pont, France

© Copyright 2025. All Rights Reserved by MedPath